Macomics to Present at Upcoming Conferences, Q3 2022

Press release

Macomics to Present at Upcoming Conferences, Q3 2022

Edinburgh and Cambridge, UK, 1 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.

• Dr Luca Cassetta, co-founder and VP Immunology of Macomics will be attending the 2022 ISEH Annual meeting, Edinburgh, 1-4 September
o Speaking at Q&A session on transition from academia to start up, 2 September

• Dr Steve Myatt, CEO of Macomics, will be attending the Sachs 22nd Annual Biotech in Europe Forum, Basel, 21-22 September
o Corporate presentation
o Participating in the Immuno-Oncology Advanced Therapeutics Panel at 15.55 21 Sept

• Dr Steve Myatt and Dr Luca Cassetta, VP Immunology of Macomics, will be attending ImmunoUK, London 29-30 September
o During Track 3: Targeting The Tumour Microenvironment on day two, 30 September, Dr Cassetta will be presenting on Targeting Tumour-Associated Macrophages Through Novel Antibody Therapeutics at 13.20 and is a panellist in the Discussion: Means Of Activating The Tumour Microenvironment at 15.40

• Dr Krzysztof Wicher, VP Head of Drug Discovery of Macomics, will be attending the Macrophage-directed Therapies Summit, Boston, 4-6 October
o Presenting in the Preclinical & Discovery session on Integrated New Macrophage Target Discovery and Validation Engine at 11.00 on 5 October

• Dr Steve Myatt will be attending Bio-Europe, Leipzig, 24-26 October

Dr Steve Myatt, CEO of Macomics said: “We continue to advance our portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic, and to invest in our target discovery platform that enables the identification and validation of novel macrophage therapeutic targets, underpinned by our deep understanding of macrophage biology.

“We are delighted that we are invited speakers at events and look forward to meeting partners, collaborators and investors face-to-face to explore opportunities to work with Macomics to maximise the opportunities for TAM-targeting therapies to address unmet needs in cancer patients.”

-Ends-

About Macomics – www.macomics.com

Macomics Ltd is an immuno-oncology company with world-leading expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.

The company was co-founded in 2020 by Prof. Jeffrey Pollard and Dr. Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology. It has R&D and office facilities in Edinburgh and Cambridge, UK and is backed by Epidarex Capital, Scottish Enterprise, and Caribou Property Limited.

Follow us on LinkedIn and https://twitter.com/MacomicsL